Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05523167




Registration number
NCT05523167
Ethics application status
Date submitted
30/08/2022
Date registered
31/08/2022
Date last updated
20/05/2024

Titles & IDs
Public title
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Scientific title
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Secondary ID [1] 0 0
ARGX-113-2007
Universal Trial Number (UTN)
Trial acronym
ALKIVIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Active Idiopathic Inflammatory Myopathy 0 0
Myositis 0 0
Dermatomyositis 0 0
Polymyositis 0 0
Immune-Mediated Necrotizing Myopathy 0 0
Antisynthetase Syndrome 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Neurological 0 0 0 0
Other neurological disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - EFG PH20 SC
Other interventions - PBO

Experimental: EFG PH20 SC - participants receiving efgartigimod PH20 SC on top of background treatment

Placebo Comparator: PBO PH20 SC - participants receiving placebo PH20 SC on top of background treatment


Other interventions: EFG PH20 SC
Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer

Other interventions: PBO
Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Total improvement score (TIS); measured on a [0,100] scale. Higher scores represent improvement; zero indicates no improvement or worsening (from baseline).
Timepoint [1] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [1] 0 0
Time to reach TIS = 20 (first "minimal clinical improvement")
Timepoint [1] 0 0
phase 2: up to 24 weeks; phase 3: up to 52 weeks
Secondary outcome [2] 0 0
Percentage of participants with TIS = 20
Timepoint [2] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [3] 0 0
Time to reach TIS = 40 (first "moderate clinical improvement")
Timepoint [3] 0 0
phase 2: up to 24 weeks; phase 3: up to 52 weeks
Secondary outcome [4] 0 0
Percentage of participants with TIS = 40
Timepoint [4] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [5] 0 0
Change in manual muscle testing-8 (MMT8) score
Timepoint [5] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [6] 0 0
Change in Patient Global Assessment of Disease Activity (PGA)
Timepoint [6] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [7] 0 0
Change in Physician Global Assessment of Disease Activity (MDGA)
Timepoint [7] 0 0
phase 2: 24 weeks; phase 3: 52 weeks
Secondary outcome [8] 0 0
Proportion of participants achieving target dose of = 5 mg (prednisone equivalent)
Timepoint [8] 0 0
phase 2: 24 weeks; phase 3: 52 weeks

Eligibility
Key inclusion criteria
- Ability to consent in the jurisdiction in which the study is taking place and capable
of giving signed informed consent.

- A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM)

- One of the following medical histories: Diagnosis of dermatomyositis (DM) or juvenile
dermatomyositis (JDM), Diagnosis of polymyositis (PM) (including antisynthetase
syndrome (ASyS)), Diagnosis of immune-mediated necrotizing myopathy (IMNM)

- Diagnosed with active disease as defined by the presence of at least 1 of the
following criteria: Abnormal levels of at least 1 of the following enzymes: creatine
kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransaminase (AST),
alanine aminotransferase (ALT), based on central laboratory results; Electromyography
demonstrating active disease within the past 3 months; Active dermatomyositis (DM)
skin rash; Muscle biopsy indicative of active idiopathic inflammatory myopathy (IIM)
in the past 3 months; Magnetic resonance imaging within the past 3 months indicative
of active inflammation

- Muscle weakness

- Receiving a permitted background treatment for idiopathic inflammatory myopathy.

- Contraceptive use consistent with local regulations, where available, for individuals
participating in clinical studies. Women of childbearing potential must have a
negative serum pregnancy test during screening and a negative urine pregnancy test at
baseline before receiving investigational medicinal product (IMP).

The full list of inclusion criteria can be found in the protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- A clinically significant active infection at screening

- A COVID-19 polymerase chain reaction (PCR)-positive test before enrollment

- Any other known autoimmune disease that, in the investigator's opinion, would
interfere with an accurate assessment of clinical symptoms of idiopathic inflammatory
myopathy (IIM) or put the patient at undue risk

- A history of malignancy unless considered cured by adequate treatment, with no
evidence of recurrence for = 3 years before the first administration of the
investigational medicinal product (IMP). Adequately treated participants with the
following cancers can be included at any time: Basal cell or squamous cell skin cancer
; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental
histological finding of prostate cancer

- Severe muscle damage

- Glucocorticoid-induced myopathy that the investigator considers the primary cause of
muscle weakness or permanent weakness linked to a non-idiopathic inflammatory myopathy
(IIM) cause

- Juvenile myositis (JDM) diagnosed > 5 years from screening or juvenile myositis with
extensive calcinosis or severe calcinosis.

- Uncontrolled interstitial lung disease or any other uncontrolled idiopathic
inflammatory myopathy (IIM) manifestation that, in the opinion of the investigator,
would be likely to require treatment with prohibited medication during the study

- Other inflammatory and noninflammatory myopathies: inclusion body myositis, overlap
myositis), metabolic myopathies, muscle dystrophies or a family history of muscle
dystrophy, drug-induced or endocrine induced myositis, and juvenile myositis (other
than juvenile dermatomyositis (JDM))

- Clinically significant disease, recent major surgery or intends to have surgery during
the study, or has any other condition in the opinion of the investigator that could
confound the results of the trial or put the patient at undue risk

- Known hypersensitivity reaction to investigational medicinal product (IMP) or 1 of its
excipients

- Received a live or live-attenuated vaccine less than 4 weeks before screening.

- Positive serum test at screening for active viral infection with any of the following
conditions: Hepatitis B virus (HBV); Hepatitis C virus (HCV); HIV

- Participant has previously participated in an efgartigimod clinical trial and received
at least 1 dose of investigational medicinal product (IMP).

- Participant is concurrently participating in any other clinical study, including a
noninterventional study.

- Participant has a current or history (ie, within 12 months of screening) of alcohol,
drug, or medication abuse.

- Participant is pregnant or lactating or intends to become pregnant during the study.

- Participant has severe renal impairment .

- Participant is institutionalized by a court or other governmental order or is in a
dependent relationship with the sponsor or investigator.

The full list of exclusion criteria can be found in the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/10/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2027
Actual
Sample size
Target
240
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Wesley Medical Research - Auchenflower
Recruitment hospital [2] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
4066 - Auchenflower
Recruitment postcode(s) [2] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Córdoba
Country [25] 0 0
Argentina
State/province [25] 0 0
La Plata
Country [26] 0 0
Argentina
State/province [26] 0 0
Ramos Mejía
Country [27] 0 0
Argentina
State/province [27] 0 0
San Miguel De Tucumán
Country [28] 0 0
Argentina
State/province [28] 0 0
San Miguel
Country [29] 0 0
Austria
State/province [29] 0 0
Innsbruck
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Belgium
State/province [32] 0 0
Liège
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Plovdiv
Country [34] 0 0
Canada
State/province [34] 0 0
Montréal
Country [35] 0 0
Canada
State/province [35] 0 0
Ottawa
Country [36] 0 0
Cyprus
State/province [36] 0 0
Nicosia
Country [37] 0 0
Denmark
State/province [37] 0 0
Copenhagen
Country [38] 0 0
France
State/province [38] 0 0
Paris
Country [39] 0 0
France
State/province [39] 0 0
Rouen
Country [40] 0 0
France
State/province [40] 0 0
Strasbourg
Country [41] 0 0
Georgia
State/province [41] 0 0
Tbilisi
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Germany
State/province [43] 0 0
Düsseldorf
Country [44] 0 0
Germany
State/province [44] 0 0
Göttingen
Country [45] 0 0
Germany
State/province [45] 0 0
Herne
Country [46] 0 0
Germany
State/province [46] 0 0
Tuebingen
Country [47] 0 0
Greece
State/province [47] 0 0
Athens
Country [48] 0 0
Greece
State/province [48] 0 0
Ioánnina
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Ireland
State/province [51] 0 0
Dublin
Country [52] 0 0
Ireland
State/province [52] 0 0
Manorhamilton
Country [53] 0 0
Italy
State/province [53] 0 0
Bari
Country [54] 0 0
Italy
State/province [54] 0 0
Firenze
Country [55] 0 0
Italy
State/province [55] 0 0
Milan
Country [56] 0 0
Italy
State/province [56] 0 0
Pavia
Country [57] 0 0
Italy
State/province [57] 0 0
Pisa
Country [58] 0 0
Italy
State/province [58] 0 0
Reggio Emilia
Country [59] 0 0
Italy
State/province [59] 0 0
Roma
Country [60] 0 0
Italy
State/province [60] 0 0
Rozzano
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Daejeon
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Incheon
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seoul
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Suwon
Country [65] 0 0
Lithuania
State/province [65] 0 0
Kaunas
Country [66] 0 0
Lithuania
State/province [66] 0 0
Vilnius
Country [67] 0 0
Mexico
State/province [67] 0 0
Mexico City
Country [68] 0 0
Netherlands
State/province [68] 0 0
Amsterdam
Country [69] 0 0
Netherlands
State/province [69] 0 0
Utrecht
Country [70] 0 0
Peru
State/province [70] 0 0
Arequipa
Country [71] 0 0
Peru
State/province [71] 0 0
Lima
Country [72] 0 0
Poland
State/province [72] 0 0
Bydgoszcz
Country [73] 0 0
Poland
State/province [73] 0 0
Szczecin
Country [74] 0 0
Portugal
State/province [74] 0 0
Lisboa
Country [75] 0 0
Serbia
State/province [75] 0 0
Belgrade
Country [76] 0 0
Serbia
State/province [76] 0 0
Belgrad
Country [77] 0 0
Spain
State/province [77] 0 0
Alicante
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona
Country [79] 0 0
Spain
State/province [79] 0 0
Madrid
Country [80] 0 0
Spain
State/province [80] 0 0
Sevilla
Country [81] 0 0
Spain
State/province [81] 0 0
Valencia
Country [82] 0 0
Spain
State/province [82] 0 0
Vigo
Country [83] 0 0
Sweden
State/province [83] 0 0
Stockholm
Country [84] 0 0
Switzerland
State/province [84] 0 0
Lugano
Country [85] 0 0
Taiwan
State/province [85] 0 0
Taichung city
Country [86] 0 0
Taiwan
State/province [86] 0 0
Taichung
Country [87] 0 0
Thailand
State/province [87] 0 0
Bangkok
Country [88] 0 0
Thailand
State/province [88] 0 0
Khon Kaen
Country [89] 0 0
Thailand
State/province [89] 0 0
Pathum Thani
Country [90] 0 0
Turkey
State/province [90] 0 0
Ankara
Country [91] 0 0
Turkey
State/province [91] 0 0
Konya
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Liverpool
Country [93] 0 0
United Kingdom
State/province [93] 0 0
London
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Middlesbrough
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
argenx
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared
with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with
the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or
certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be
included in the study. Treatment response will be measured by Total improvement score (TIS).
Additional information can be found on https://myositis-study.com/.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05523167
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Sabine Coppieters, MD
Address 0 0
Country 0 0
Phone 0 0
857-350-4834
Fax 0 0
Email 0 0
ClinicalTrials@argenx.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05523167